Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study
: In this real-world cohort, systemic fibrinolysis was not associated with improved survival compared with anticoagulation alone, consistent with current guideline recommendations against routine fibrinolysis in intermediate-risk PE.
Authors
- Pablo Demelo‐Rodríguez (ORCID: https://orcid.org/0000-0002-3096-4711)
- I. Sousa-Casasnovas
- Eva Cervilla‐Muñoz (ORCID: https://orcid.org/0000-0003-2335-9529)
- Rubén Alonso-Beato (ORCID: https://orcid.org/0000-0001-5492-7061)
- Marina López‐Rubio (ORCID: https://orcid.org/0000-0001-8627-304X)
- Lucía Ordieres‐Ortega (ORCID: https://orcid.org/0000-0002-6094-1633)
- Miriam Juárez-Fernández
- Luis-Antonio Alvarez-Sala Walther
- Francisco Galeano-Valle
Institutions
- Universidad Complutense de Madrid (ES)
- Instituto de Salud Carlos III (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Centro de Investigación Biomédica en Red (ES)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-12
- DOI
- https://doi.org/10.3390/jcm15082932
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- LEO Pharma